Cassava Sciences, Inc. (NASDAQ:SAVA)
Industry: Biotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Current Quote*
Last: $2.080
Change: 1.000
Book: $5.511
Volume: 1,011,553

As Of: 07/08 16:16 ET
*Quotes delayed by 20min.

Graphs for SAVA


3 Month Graph


6 Month Graph


1 Year Graph